On Wednesday, Shares of Hertz Global Holdings Inc (NYSE:HTZ), lost -3.14% to $14.06.
The Hertz Corporation (HTZ) is launching its annual Winter Sale to provide customers with great savings on vehicle hire in more than 100 countries, for rentals collected from January 1st, 2016, to March 31st, 2016. Members of Hertz’s loyalty program Gold Plus Rewards will benefit from the Winter Sale’s early access, with discounted rates on rentals booked from December 24th, 2015.
For bookings made between December 30th, 2015 and January 31st, 2016, customers will enjoy discounts up to 25% for qualifying domestic or outbound rentals in Europe, the Middle East and Africa, up to 20% in Asia Pacific, and 20% in Latin America and the Caribbean. In addition, the sale offers 18% savings on qualified outbound rentals to North America. Discounted Hertz van rental is also offered in Germany, France, Italy, Spain, Switzerland and UK. Saving will be applied by quoting the customer discount promotion (CDP) code “816220” when booking online at www.hertz.com or by calling Hertz.
Additionally, Hertz Gold Plus Rewards members booking their vehicle between December 24th, 2015 and January 31st, 2016 can benefit from savings of up to 30% on qualifying domestic or outbound rentals in Europe, the Middle East and Africa. Members booking during that period in any other destinations can enjoy Hertz Winter Sale’s discounts available to all customers. The rentals made through the sale will also qualify for loyalty points and reward days through the Hertz Gold Plus Rewards program. Special Winter Sale’s savings for Gold Plus Rewards members will be applied by quoting the CDP code “816225” when booking online or over the phone.
Hertz Global Holdings, Inc., through its auxiliaries, rents and leases cars and trucks in the United States and internationally. It operates in four segments: U.S. Car Rental, International Car Rental, Worldwide Equipment Rental, and All Other Operations.
Shares of Seagate Technology PLC (NASDAQ:STX), inclined 0.08% to $37.18, during its last trading session.
Starrex International Ltd. declares that, further to its news release dated December 9, 2015, the Company has determined to restate and re-file: (i) its first, second and third quarter unaudited interim financial statements for the periods ended March 31, June 30 and September 30, 2015 (originally filed on May 29, August 28 and November 30, 2015); (ii) the corresponding administration’s negotiations and analyses for the quarterly periods ended March 31, June 30 and September 30, 2015 (originally filed on May 29, August 28 and November 30, 2015); and (iii) the administration’s negotiation and analysis for the year ended December 31, 2014, originally filed on April 30, 2015.
The changes to the interim financial statements for 2015 arise principally out of the allocation of the valuations of the acquisitions accomplished by the Company on July 9, 2014, together with the divestitures effective May 1, 2015. The changes will comprise disclosure of the valuation process for the acquisitions, subsequent divesture allocations and the corresponding impact on the applicable financial statements and the accounting treatment therein.
The Company intends to file the amended and restated interim financial statements, the corresponding administration’s negotiations and analyses, and the administration’s negotiation and analysis for the year ended December 31, 2014, by January 22, 2016.
Seagate Technology Public Limited Company designs, manufactures, and sells electronic data storage products in the Asia Pacific, the Americas, and EMEA countries. It provides hard disk drives, solid state hybrid drives, solid state drives, PCIe cards, and serial advanced technology architecture controllers that are designed for enterprise servers and storage systems in mission critical and nearline applications; for client compute applications comprising desktop and mobile computing; and for client non-compute applications, such as digital video recorders, personal data backup systems, portable external storage systems, digital media systems, and surveillance systems.
Finally, Discovery Laboratories, Inc. (NASDAQ:DSCO), ended its last trade with -3.72% loss, and closed at $0.218.
Discovery Laboratories, declared that it has initiated its AEROSURF® phase 2b clinical trial in premature infants 26 to 32 weeks gestational age (GA) receiving non-invasive nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS). The trial is designed to evaluate premature infants receiving aerosolized KL4 surfactant (counting potentially repeat doses) contrast to nCPAP alone. Two dose groups will be evaluated. The primary objective of the trial is to demonstrate evidence of efficacy and, if successful, inform the design of a phase 3 clinical program.
“Presently, surfactant therapy is primarily administered to premature infants with RDS via invasive endotracheal intubation. The trend in neonatology is to use less- or non-invasive methods to treat RDS but these preclude the administration of surfactant therapy in a timely manner. AEROSURF allows for non-invasive delivery of aerosolized KL4 surfactant to premature infants receiving nCPAP,” commented Steve Simonson, M.D., Discovery Labs’ Chief Development Officer. “The initiation of the phase 2b trial is an important next step to build upon the results observed in our recently accomplished phase 2a clinical trials in premature infants 29 to 34 weeks GA. Data from these trials are encouraging and suggest that AEROSURF may reduce the incidence of nCPAP failure and the need for intubation and delayed surfactant therapy. If this result is confirmed as we advance our development program, AEROSURF could represent a noteworthy medical advancement in neonatology.”
The AEROSURF phase 2b trial is a multicenter, randomized, controlled study with masked treatment assignment in premature infants 26 to 32 weeks GA receiving nCPAP for RDS. The trial is designed to evaluate aerosolized KL4 surfactant administered in two dose groups (25 and 50 minutes), counting the ability for infants to receive repeat doses, contrast to premature infants receiving standard care of nCPAP alone. The following endpoints will be evaluated: time to nCPAP failure (the need for intubation and delayed surfactant therapy), incidence of nCPAP failure and physiological parameters indicating the effectiveness of lung function. The trial will enroll up to 250 premature infants at up to 50 sites in the United States, Canada, Europe and Latin America. Enrollment in the phase 2b trial is starting with premature infants 29 to 32 weeks GA, followed by premature infants 26 to 28 weeks GA after completion of the ongoing phase 2a trial in this age group.
Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical-care patients with respiratory disease and improving care in pulmonary medicine. Its proprietary drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant in liquid, lyophilized, and aerosolized dosage forms), in addition to develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant.
